×
About 13,837 results

ALLMedicine Hypertrophic Cardiomyopathy Center

Research & Reviews  6,565 results

Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Sym...
https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853
Circulation. Heart Failure; Ho CY, Olivotto I et. al.

Jun 4th, 2020 - Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving...

The novel duplication HRAS c.186_206dup p.(Glu62_Arg68dup): clinical and functional asp...
https://doi.org/10.1038/s41431-020-0662-4
European Journal of Human Genetics : EJHG; Gripp KW, Baker L et. al.

Jun 3rd, 2020 - Specific activating missense HRAS variants cause Costello syndrome (CS), a RASopathy with recognizable facial features. The majority of these dominant disease causing variants affect the glycine residues in position 12 or 13. A clinically suspecte...

Characterization of interstitial diffuse fibrosis patterns using texture analysis of my...
https://doi.org/10.1371/journal.pone.0233694
PloS One; El-Rewaidy H, Neisius U et. al.

Jun 1st, 2020 - The pattern of myocardial fibrosis differs significantly between different cardiomyopathies. Fibrosis in hypertrophic cardiomyopathy (HCM) is characteristically as patchy and regional but in dilated cardiomyopathy (DCM) as diffuse and global. We s...

Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.
https://doi.org/10.1161/CIRCHEARTFAILURE.120.007000
Circulation. Heart Failure; Caravita S, Baratto C et. al.

Jun 1st, 2020 - Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.|2020|Caravita S,Baratto C,Perego GB,Cecchi F,Crotti L,|

The Impact of Syndromic Genetic Disorders on Medical Management and Mortality in Pediat...
https://doi.org/10.1007/s00246-020-02373-4
Pediatric Cardiology; Edelson JB, Griffis H et. al.

May 31st, 2020 - Hypertrophic cardiomyopathy (HCM) is a prevalent cardiomyopathy in children, with variable etiologies, phenotypes, and associated syndromic genetic disorders (GD). The spectrum of evaluation in this heterogeneous population has not been well descr...

see more →

Guidelines  13 results

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy
https://jamanetwork.com/journals/jamacardiology/fullarticle/2733139

May 21st, 2019 - Question Is it possible to identify most patients with hypertrophic cardiomyopathy (HCM) at risk of arrhythmic sudden cardiac death (SCD) and to prevent such events with prophylactic implantable cardioverter/defibrillators (ICDs)? Findings In t...

Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JC...
https://doi.org/10.1253/circj.CJ-66-0122
Circulation Journal : Official Journal of the Japanese Circulation Society;

Feb 4th, 2016 - Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012) - Digest Version .|2016| ,|diagnosis,physiopathology,therapy,

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Tas...
https://doi.org/10.1093/eurheartj/ehu284
European Heart Journal; , Elliott PM et. al.

Aug 31st, 2014 - 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).|2014| ,Elliott PM,Anastasakis A,Borger MA,B...

2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:...
https://doi.org/10.1016/j.jtcvs.2011.10.019
The Journal of Thoracic and Cardiovascular Surgery; , et. al.

Nov 18th, 2011 - 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.|2011| , , , , ,|diag...

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy:...
https://doi.org/10.1016/j.jacc.2011.06.011
Journal of the American College of Cardiology; Gersh BJ, Maron BJ et. al.

Nov 14th, 2011 - 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the Ame...

see more →

Clinicaltrials.gov  6,889 results

Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Sym...
https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853
Circulation. Heart Failure; Ho CY, Olivotto I et. al.

Jun 4th, 2020 - Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving...

The novel duplication HRAS c.186_206dup p.(Glu62_Arg68dup): clinical and functional asp...
https://doi.org/10.1038/s41431-020-0662-4
European Journal of Human Genetics : EJHG; Gripp KW, Baker L et. al.

Jun 3rd, 2020 - Specific activating missense HRAS variants cause Costello syndrome (CS), a RASopathy with recognizable facial features. The majority of these dominant disease causing variants affect the glycine residues in position 12 or 13. A clinically suspecte...

Characterization of interstitial diffuse fibrosis patterns using texture analysis of my...
https://doi.org/10.1371/journal.pone.0233694
PloS One; El-Rewaidy H, Neisius U et. al.

Jun 1st, 2020 - The pattern of myocardial fibrosis differs significantly between different cardiomyopathies. Fibrosis in hypertrophic cardiomyopathy (HCM) is characteristically as patchy and regional but in dilated cardiomyopathy (DCM) as diffuse and global. We s...

Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.
https://doi.org/10.1161/CIRCHEARTFAILURE.120.007000
Circulation. Heart Failure; Caravita S, Baratto C et. al.

Jun 1st, 2020 - Invasive Hemodynamics of Hypertrophic Cardiomyopathy: Exercise Versus Isoproterenol.|2020|Caravita S,Baratto C,Perego GB,Cecchi F,Crotti L,|

The Impact of Syndromic Genetic Disorders on Medical Management and Mortality in Pediat...
https://doi.org/10.1007/s00246-020-02373-4
Pediatric Cardiology; Edelson JB, Griffis H et. al.

May 31st, 2020 - Hypertrophic cardiomyopathy (HCM) is a prevalent cardiomyopathy in children, with variable etiologies, phenotypes, and associated syndromic genetic disorders (GD). The spectrum of evaluation in this heterogeneous population has not been well descr...

see more →

News  337 results

Mavacamten Phase 2 Results Hopeful in Nonobstructive Hypertrophic Cardiomyopathy
https://www.medscape.com/viewarticle/931112

May 25th, 2020 - An investigational, first-in-class agent showed hypothesis-generating promise in symptomatic adults with nonobstructive hypertrophic cardiomyopathy (HCM), a condition lacking in good treatment options, in an early dose-finding study. The 40 patien...

Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know
https://www.medscape.com/viewarticle/930827

May 21st, 2020 - Hypertrophic cardiomyopathy (HCM) is the most common inherited monogenic cardiac disorder, affecting 0.2-0.5% of the population.[1,2] In the United States, 750,000 people are estimated to have HCM; however, only approximately 100,000 people have b...

Functional Gains From Novel Agent for Obstructive HCM, Top-line Results
https://www.medscape.com/viewarticle/930383

May 11th, 2020 - Patients with obstructive hypertrophic cardiomyopathy (HCM) who took an investigational agent that targets cardiac myosin over about 7 months showed across-the-board improvements in functional capacity, symptoms, and left ventricular outflow obstr...

Ultra-Low Risk of Sudden Cardiac Death Seen in HCM Challenges Prevailing Views
https://www.medscape.com/viewarticle/920713

Oct 31st, 2019 - The risk for sudden cardiac death (SCD) in adolescents and young adults with hypertrophic cardiomyopathy (HCM) is "an order of magnitude lower" than most recent estimates would indicate, a report based on comprehensive autopsy data suggests. The a...

New Algorithm Can Help Predict Sudden-Death Risk in Kids With Hypertrophic Cardiomyopathy
https://www.medscape.com/viewarticle/917220

Aug 26th, 2019 - NEW YORK (Reuters Health) - Researchers have developed a new model to predict the individualized risk of sudden cardiac death (SCD) in children with hypertrophic cardiomyopathy. Although the risk of SCD in this population is higher than that in ad...

see more →

Patient Education  33 results see all →